Insulin, discovered in 1921, was first used in 1922. At the time, it was considered medical miracle that changed the diagnosis for those living with type 1 diabetes from a death sentence to a manageable condition. Today, all those living with type 1 diabetes, and an estimated 63 million living with type 2 diabetes, use insulin. Despite the fact that insulin has been used for nearly 100 years, an estimated 1 in 2 people who need it cannot afford and/or access this much-needed medicine. Since its inception in 2015, HAI’s Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS) Study has been working to identify and address the inequities and inefficiencies in the global insulin market.

Phase I (2015-2018)

In it’s initial phase, ACCISS produced a comprehensive, first-of-its-kind evidence base of the global insulin market. In doing so, it created innovative policies, tools and interventions to overcome barriers to insulin access globally, which have have been brought together under the  ACCISS Toolkit.

Phase II (2018-2021)

The second phase focuses on piloting the tools and interventions developed in Phase I at country level, while continuing to work globally to address inequities and inefficiencies in the insulin market. Our Phase II workstreams are:

  1. Work with global partners to develop evidence-based tools that address worldwide barriers to insulin access, and strengthen tools already developed
  2. Develop, with national partners in four countries, comprehensive and contextualised national strategies to address the range of challenges that people requiring insulin face, and to pilot and evaluate the interventions
  3. Further expand the ACCISS network and develop civil society networks, amplified in international/regional/national fora, to reduce, or eliminate, the barriers to insulin access

The study is co-led by Dr Margaret Ewen and Molly Lepeska (HAI), Dr David Beran (Geneva University Hospitals and the University of Geneva), and Professor Richard Laing (Boston University School of Public Health). The study also brings together a large group of leading international experts as members of its Advisory Group. The study is funded by a grant from The Leona M. and Harry B. Helmsley Charitable Trust and Stichting ICF.